Article
Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183
2021-05-14
Abstract excerpt
Drug resistance and a dire lack of transmission-blocking antimalarials hamper malaria elimination. Here, we present the pantothenamide MMV693183 as a first-in-class acetyl-CoA synthetase (ACS) inhibitor to enter preclinical development. Our studies demonstrated attractive drug-like properties and in vivo efficacy in a humanized mouse model of Plasmodium falciparum infection. The compound showed exceptional in v...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- b1c65339-302b-5b85-a9b3-d06d9098ad64
- DOI
- 10.1101/2021.05.12.443866
